ClinicalTrials.gg
CompletedNCT00234403Updated Apr 23, 2009

A Trial to Evaluate the Combination of Iressa & Faslodex® in Patients With Advanced or Metastatic Breast Cancer

A Phase 2 interventional study of gefitinib and fulvestrant in Breast Cancer, sponsored by AstraZeneca. Completed at 7 sites in Spain. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-04-23.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing gefitinib in Breast Neoplasms — none open to participants now, none under way, none of them phase 3. Gefitinib · Breast Neoplasms.

Enrollment
7th of 18
60 · median 52
Started
2004
with 4 others
Phase 2
16 of 18
none open now
Registered
11th of 18
by date
Lead sponsor
8 of 18
AstraZeneca

Among the 18 studies testing gefitinib in Breast Neoplasms, this one is the 7th largest by enrollment, is one of 5 that started in 2004, is one of 16 in phase 2, and was the 11th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

None of the 18 studies testing gefitinib in Breast Neoplasms is open now. The open studies under Breast Neoplasms, anywhere →

About gefitinib

Gefitinib: first FDA approval 2003 (IRESSA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies testing gefitinib in Breast Neoplasms as a file.
02

Study summary

The progression free survival and efficacy of 250 mg ZD1839 in combination with a fixed dose of fulvestrant 250 mg im once a month will be evaluated in female patients with histologically-confirmed advanced or metastatic, ER and/or PR positive breast cancer

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • Advanced breast cancer
  • Metastatic breast cancer
  • ER positive breast cancer
  • PR positive breast cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed advanced or breast cancer
  • females with amenorrhoea > 12 months and an intact uterus
  • FSH levels within postmenopausal range or have undergone a bilateral oophorectomy
  • ER \&/or PR positive
  • previous hormone therapy > 12 months prior to enrolment
  • previous adjuvant chemotherapy > 6 months prior to enrolment
  • according to and/or non measurable bone disease
  • of at least 12 weeks
  • World Health Organisation (WHO) performance status (PS) of 0 to 1.

Exclusion criteria

Exclusion Criteria:

  • Male
  • life-threatening visceral disease
  • evidence of clinically active interstitial lung disease
  • ER and PR negative
  • treatment with LHRH analogues \< 3 months prior to enrolment
  • patients who have restarted menses or do not have FSH levels within the range
  • treatment with strontium - 90 (or other radio pharmaceutical) within the previous 3 months
  • Treatment with hormonotherapy and/or chemotherapy for advanced disease
  • extensive radiotherapy to within the last 4 weeks (i.e. >30% of bone marrow, e.g. whole of pelvis or half of spine)
  • currently receiving oestrogen replacement therapy
  • treatment with a non-approved or experimental drug within 4 weeks before enrolment
  • (ANC) less than 1.5 x 109/litre (L) or less than 100 x 109/L , serum greater than 1.25 times the upper limit of reference range (ULRR, serum creatinine greater than 1.5 mg/dL, (ALT) or aspartate aminotransferase (AST) greater than 2.5 times the ULRR if no demonstrable liver metastases, or greater than 5 times the ULRR in the presence of liver metastases, history of bleeding diathesis or long term or present anticoagulant therapy (other than antiplatelet therapy
  • any unresolved chronic toxicity greater than CTC grade 2 from previous anticancer therapy
  • concomitant use of phenytoin, carbamazepine, barbiturates, rifampicin, known
  • severe to ZD1839 or fulvestrant or any of the of this product.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants

Interventions

06

What researchers measure

Primary outcomes

  1. To evaluate the progression-free survival (PFS) of the combination of 250 mg ZD1839 and fulvestrant in patients with advanced or metastatic breast cancer

Secondary outcomes

  1. To estimate the objective response rate (complete response [CR] and partial response [PR]) at trial closure.

  2. To estimate the disease control rate at trial closure.

  3. To estimate overall survival.

  4. To evaluate the safety & tolerability of the combination gefitinib and fulvestrant

07

Study locations

7 sites
  • Investigative Site
    Alicante, Spain
  • Investigative Site
    Gerona, Spain
  • Investigative Site
    Jaen, Spain
  • Investigative Site
    Madrid, Spain
  • Investigative Site
    Seville, Spain
  • Investigative Site
    Valencia, Spain
  • Investigative Site
    Zaragoza, Spain
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2004 and a completion of Oct 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 5, 2005
First posted
Oct 7, 2005
Start
May 2004
CompletionActual
Oct 2007
Last update
Apr 23, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00234403
Lead sponsor
AstraZeneca
First posted
Oct 7, 2005
Start date
May 2004
Completion
Oct 2007
Last update
Apr 23, 2009

Study contacts

AstraZeneca Spain Medical Director, MD
study director · AstraZeneca
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Gefitinib · Fulvestrant

Start the discussion